This article defines some of the terms used in chiral chemistry and some of the basic mechanistic issues that arise in stereochemistry in pharmacology. Attention is also drawn to the impact of stereochemistry on drug regulation and its significance for new drug development. The stereoselectivity of drugs is underpinned by the fact that the human body is essentially a chiral structure. The rationale for development of chiral drugs is the suggestion that single stereoisomer drugs would provide superior therapy by allowing reductions in dosage, reduced variability in metabolism and response, simpler dose-response relationships and improved tolerability.
chiral drug; stereoisomer; enantiomer; stereochemistry; stereopharmacology
Almansa C, Gomez LA, Cavalcanti FL, de Arriba AF, Rodriguez R, Carceller E, Garcia-Rafanell J, Forn J: Diphenylpropionic acids as new AT1 selective angiotensin II antagonists. J Med Chem 39:2197-2206, 1996.
Ariens EJ: Stereochemistry, a basis for sophisticated nonsense in pharmacokinetics and clinical pharmacology. Eur J Clin Pharmacol 26:663-668, 1984.
Burke WJ, Kratochvil ChJ: Stereoisomers in psychiatry: the case of escitalopram. J Clin Psychiatry 4:20-24, 2002.
Cahn RS, Ingold CK, Prelog V: Specification of molecular chirality. Angew Chem 78:413-447, 1966.
Cheng H, Rogers JD, Demetriades JL, Holland SD, Seibold JR, Depuy E: Pharmacokinetics and bioinversion of ibuprofen enantiomers in humans. Pharm Res 11:824-830, 1994.
Chon EM, Middleton RK: Labetalol hepato toxicity. Ann Pharmacother 26:344-345, 1992.
Herdevall BM, Klinge B, Persson L, Huledal G, Abdel-Rehim M: Plasma levels of lidocaine, o-toluidine, and prilocaine after application of 8.5 g Oraqix in patients with generalized periodontitis: effect on blood methemoglobin and tolerability. Acta Odontol Scand 61:230-234, 2003.
Hutt AJ, Tan SC: Drug chirality and its clinical significance. Drugs 52, Suppl. 2:1-12, 1996.
Lalonde RL, O'Rear TL, Wainer IW, Drda KD, Herring VL, Bottorff MB: Labetalol pharmacokinetics and pharmacodynamics: evidence of stereoselective disposition. Clin Pharmacol Ther 48:509-519, 1990.
Palareti G, Legnani C: Warfarin withdrawal. pharmacokinetic-pharmacodynamic considerations. Clin Pharmacokinet 30:300-313, 1996.
Patocka J, Plucar B: Pharmacology and toxicology of absinthe. J Appl Biomed 1:199-205, 2003.
Pohl LR, Bales R, Trager WF: Warfarin - stereochemical aspects of its metabolism in vivo in the rat. Res. Commun Chem Pathol Pharmacol 15:233-256, 1976.
Rybak LP, Whitworth C: Ototoxicity of indacrinone is stereospecific. Hear Res 31:169-174, 1987.
Sanchez C, Bergqvist PB, Brennum LT, Gupta S, Hogg S, Larsen A, Wiborg O: Escitalopram, the S-(+)-enantiomer of citalopram, is a selective serotonin reuptake inhibitor with potent effects in animal models predictive of antidepressant and anxiolytic activities. Psychopharmacology (Berl). 167:353-362, 2003.
Schwarz UI: Clinical relevance of genetic polymorphisms in the human CYP2C9 gene. Eur J Clin Invest 33, Suppl. 2:23-30, 2003.
Hashim NH, Shafie S, Khan SJ. Enantiomeric fraction as an indicator of pharmaceutical biotransformation during wastewater treatment and in the environment - a review. Environ Technol. 31: 1349-1370, 2010.
Nunez MC, Garcia-Rubino ME, Conejo-Garcia A, Cruz-Lopez O, Kimatrai M, Gallo MA, Espinosa A, Campos JM. Homochiral Drugs: A Demanding Tendency of the Pharmaceutical Industry. Curr Med Chem. 16: 2064-2074, 2009.
Ivanov IT, Tsokeva Z. Effect of Chirality on PVP/Drug Interaction Within Binary Physical Mixtures of Ibuprofen, Ketoprofen, and Naproxen: A DSC Study. Chirality. 21: 719-727, 2009.
Valliappan K, Kannan K, Sivakumar T, Manavalan R. Enantiospecific pharmacokinetic studies on ketoprofen in tablet formulation using indirect chiral HPLC analysis. J Appl Biomed. 4: 153-161, 2006.